12月19日 - ** Altimmune ALT.O股价盘前上涨5.9%至5.33美元
** 该药物开发商称，在一项名为MASH的脂肪肝患者中期研究中，其试验性GLP-1药物在治疗48周后改善了肝脏瘢痕和肝脏健康状况。
** 服用 1.8 毫克较高剂量培美度肽的患者在 48 周后体重平均减轻了 7.5%
** 截至上次收盘，该公司股价年累计下跌30
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.